The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Exploring the association between KRAS mutations and depression in non-small cell lung cancer (NSCLC) patients.
 
Jenny Jing Li
No Relationships to Disclose
 
Jessica Harper
No Relationships to Disclose
 
Nizar Bhulani
No Relationships to Disclose
 
David E. Gerber
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Bristol-Myers Squibb; Samsung Bioepis
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - ArQule (Inst); BerGenBio (Inst); ImClone Systems (Inst); Immunogen (Inst); Karyopharm Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books.
Travel, Accommodations, Expenses - ArQule; Bristol-Myers Squibb; Lilly; Lilly
 
Saad A. Khan
Honoraria - ARIAD; EMD Serono; Genentech/Roche; Genzyme
Consulting or Advisory Role - ARIAD; EMD Serono; Genentech/Roche
Speakers' Bureau - Genzyme
Research Funding - Abbvie (Inst); Bayer/Onyx (Inst); Celldex (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Threshold Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Novartis
 
Alejandra Madrigales
No Relationships to Disclose
 
Samantha Gates
No Relationships to Disclose
 
Marisa Toups
No Relationships to Disclose
 
Muhammad Shaalan Beg
Consulting or Advisory Role - Celgene; Genentech/Roche; Guardant Health; Ipsen; Merrimack
Speakers' Bureau - Ipsen
Research Funding - Bristol-Myers Squibb; Celgene; MedImmune; miRNA Therapeutics